ERBB2 and cancer: Trastuzumab (Herceptin) binds to the extracellular domain IV of HER2, inhibits the ligand-independent HER2/HER3/PI3K signaling complex, enhances antibody-dependent cellular cytotoxicity (ADCC), and ultimately leads to cancer cell death [47,48].